Skip to content

A multicenter randomized clinical trial investigating the cost-effectiveness of treatment strategies with or without antibiotics for uncomplicated acute diverticulitis

A multicenter randomized clinical trial investigating the cost-effectiveness of treatment strategies with or without antibiotics for uncomplicated acute diverticulitis - DIABOLO trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON32858
Enrollment
533
Registered
2009-09-17
Start date
2010-06-05
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complicated diverticular disease infection of diverticula

Interventions

Intervention: Conservative strategy with antibiotics: supportive measures and at least 48 hours of intravenous antibiotics (and therefore admittance to the hospital) and subsequently switch to oral

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Only left-sided uncomplicated (mild) acute diverticulitis; 2. Clinical suspicion of acute diverticulitis. For acute diagnostic work-up: ultrasound or CT proven diverticulitis. In the case of diverticulitis-negative ultrasound in clinically suspected patients an intravenous contrast-enhanced CT scan is mandatory for confirmation of diverticulitis or exclusion of other pathology. CT for Hinchey/Ambrosetti classification (which is a CT-based classification system) is needed for all patients, but can be delayed 1 day in those with ultrasound diagnosis. Staging diverticultis is defined according the modified Hinchey/Ambrosetti staging, only stages 1a and 1b and "mild" diverticulitis are included; 3. All patients with informed consent.

Exclusion criteria

Exclusion criteria: 1. Previous radiological (ultrasound and/or CT) proven episode of diverticulitis; 2. Colonic cancer; 3. Inflammatory bowel disease (ulcerative colitis, Crohn's disease); 4. Hinchey stages 2, 3 and 4 or "severe" diverticulitis according to the Ambrosetti criteria, which require surgical or percutaneous treatment; 5. Disease with expected survival of less than 6 months; 6. Contraindication for the use of the study medication (e.g. patients with advanced renal failure or allergy to antibiotics used in this study); 7. Pregnancy, breastfeeding; 8. ASA (American Society of Anaesthesiologists) classification > III; 9. Immunocompromised patients; 10. Clinical suspicion of bacteraemia (i.e. sepsis); 11. The inability of reading/understanding and filling in the questionnaires; 12. Antibiotic use in the 4 weeks before admittance.

Design outcomes

Primary

MeasureTime frame
The primary endpoint is time-to-recovery with a 6-month follow-up period.

Secondary

MeasureTime frame
Secondary endpoints are time to discharge from hospital, occurrence of complicated diverticulitis requiring surgery or percutaneous treatment, morbidity, health related quality of life, readmission rate, recurrence rate, medical and non-medical costs, and antibiotic resistance/sensitivity.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)